Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Rheumatologie
Erschienen in: Zeitschrift für Rheumatologie 8/2011

01.10.2011 | CME Weiterbildung · Zertifizierte Fortbildung

Psoriasisarthritis

Eine bleibende Herausforderung für Rheumatologen und Patienten – Teil 1: Epidemiologie, Pathogenese und Klinik

verfasst von: S. Finzel, M. Englbrecht

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch ihre Symptomvielfalt und die damit verbundenen Folgen für den Patienten zählt die Psoriasisarthritis zu einer der großen Herausforderungen in der Rheumatologie. Oft ist bei der Behandlung die fachübergreifende Zusammenarbeit von Allgemeinmedizinern, Dermatologen und Rheumatologen gefragt, die heute aufgrund neuer Klassifikationskriterien wie auch neuer bildgebender Verfahren die Krankheit frühzeitig erkennen und angemessene Therapien einleiten können. Trotzdem stellt die Rückführung des Erkrankungsbeginns auf eine oder mehrere bestimmte Ursachen nach wie vor eine Herausforderung dar, die zusätzlich durch das Fehlen krankheitsspezifischer Serumparameter erschwert wird.
Literatur
1.
Alibert J (1818) Précis théorique et pratique sur les maladies de la peau. Caille & Ravier, Paris
2.
3.
Farber E, Nall M (1998) Epidemiology: natural history and genetics. In: Roenigk H, Maibach H (Hrsg) Psoriasis. Marcel Dekker, New York, S 107–158
4.
Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160:1040–1047PubMedCrossRef
5.
Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441–447PubMedCrossRef
6.
7.
Veale DJ, FitzGerald O (2002) Psoriatic arthritis – pathogenesis and epidemiology. Clin Exp Rheumatol 20(6 Suppl 28):S27–S33PubMed
8.
Espinoza LR, Solingen R van, Cuellar ML, Angulo J (1998) Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci 316:271–276PubMedCrossRef
9.
Gladman DD, Farewell VT, Pellett F et al (2003) HLA is a candidate region for psoriatic arthritis: evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64:887–889PubMedCrossRef
10.
Gladman DD, Anhorn KA, Schachter RK, Mervart H (1986) HLA antigens in psoriatic arthritis. J Rheumatol 13:586–592PubMed
11.
Espinoza LR, Vasey FB, Gaylord SW et al (1982) Histocompatibility typing in the seronegative spondyloarthropathies: a survey. Semin Arthritis Rheum 11:375–381PubMedCrossRef
12.
Liu Y, Helms C, Liao W et al (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4(3):e1000041PubMedCrossRef
13.
Eastmond CJ, Woodrow JC (1977) The HLA system and the arthropathies associated with psoriasis. Ann Rheum Dis 36:112–120PubMedCrossRef
14.
Gladman DD, Farewell VT, Kopciuk KA, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25:730–733PubMed
15.
Chandran V, Gladman DD (2010) Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 12:288–294PubMedCrossRef
16.
Gonzalez S, Martinez-Borra J, Torre-Alonso JC et al (1999) The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 42:1010–1016PubMedCrossRef
17.
Gonzalez S, Brautbar C, Martinez-Borra J et al (2001) Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 62:632–638PubMedCrossRef
18.
Danning CL, Illei GG, Hitchon C et al (2000) Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43:1244–1256PubMedCrossRef
19.
Partsch G, Steiner G, Leeb BF et al (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518–523PubMed
20.
Hohler T, Kruger A, Schneider PM et al (1997) A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 109:562–565PubMedCrossRef
21.
Balding J, Kane D, Livingstone W et al (2003) Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48:1408–1413PubMedCrossRef
22.
Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA (1999) Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 135:546–552PubMedCrossRef
23.
McQueen FM, Skinner MA, Krissansen GW et al (1994) Natural killer cell function and expression of beta 7 integrin in psoriatic arthritis. J Rheumatol 21:2266–2273PubMed
24.
Martin MP, Nelson G, Lee JH et al (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818–2822PubMed
25.
Lesage S, Zouali H, Cezard JP et al (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70:845–857PubMedCrossRef
26.
Vermeire S, Wild G, Kocher K et al (2002) CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 71:74–83PubMedCrossRef
27.
Nair RP, Henseler T, Jenisch S et al (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 6:1349–1356PubMedCrossRef
28.
Lee FI, Bellary SV, Francis C (1990) Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol 85:962–963PubMed
29.
Karason A, Gudjonsson JE, Upmanyu R et al (2003) A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72:125–131PubMedCrossRef
30.
Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii37–ii39; discussion ii40–ii41PubMedCrossRef
31.
Trembath RC, Clough RL, Rosbotham JL et al (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813–820PubMedCrossRef
32.
Tomfohrde J, Silverman A, Barnes R et al (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264(5162):1141–1145PubMedCrossRef
33.
Matthews D, Fry L, Powles A et al (1996) Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet 14(2):231–233PubMedCrossRef
34.
Capon F, Novelli G, Semprini S et al (1999) Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol 112(1):32–35PubMedCrossRef
35.
Enlund F, Samuelsson L, Enerback C et al (1999) Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet 7(7):783–790PubMedCrossRef
36.
Lee YA, Ruschendorf F, Windemuth C et al (2000) Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13. Am J Hum Genet 67(4):1020–1024PubMedCrossRef
37.
Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38(1):7–13PubMedCrossRef
38.
Zhang XJ, He PP, Wang ZX et al (2002) Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. J Invest Dermatol 119(6):1361–1366PubMedCrossRef
39.
Guilhou JJ, Andary M, Clot J (1984) Immunological aspects of psoriasis. VI. Impairment of isoprenaline and theophylline-induced inhibition of mitogen responsiveness. Br J Dermatol 110(4):417–422PubMedCrossRef
40.
Trentham DE, Kammer GM, McCune WJ, David JR (1981) Autoimmunity to collagen: a shared feature of psoriatic and rheumatoid arthritis. Arthritis Rheum 24(11):1363–1369PubMedCrossRef
41.
Krueger GG, Bergstresser PR, Lowe NJ et al (1984) Psoriasis. J Am Acad Dermatol 11(5 Pt 2):937–947PubMedCrossRef
42.
Espinoza LR, Aguilar JL, Espinoza CG et al (1994) Fibroblast function in psoriatic arthritis. I. Alteration of cell kinetics and growth factor responses. J Rheumatol 21(8):1502–1506PubMed
43.
Saiag P, Coulomb B, Lebreton C et al (1985) Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science 230(4726):669–672PubMedCrossRef
44.
Neumuller J, Dunky A, Burtscher H et al (2001) Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 98:143–152PubMedCrossRef
45.
Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887PubMedCrossRef
46.
Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699–711PubMedCrossRef
47.
Ellis CN, Fradin MS, Messana JM et al (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324:277–284PubMedCrossRef
48.
Murphy FP, Coven TR, Burack LH et al (1999) Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol 135:1495–1502PubMedCrossRef
49.
Gottlieb SL, Gilleaudeau P, Johnson R et al (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442–447PubMedCrossRef
50.
Lebwohl M, Christophers E, Langley R et al (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719–727PubMedCrossRef
51.
Abrams JR, Lebwohl MG, Guzzo CA et al (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–1252PubMedCrossRef
52.
Panayi GS (1994) Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 8:419–427PubMedCrossRef
53.
Costello PJ, Winchester RJ, Curran SA et al (2001) Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 166:2878–2886PubMed
54.
Curran SA, FitzGerald OM, Costello PJ et al (2004) Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 172:1935–1944PubMed
55.
Tassiulas I, Duncan SR, Centola M et al (1999) Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 60:479–491PubMedCrossRef
56.
Borgato L, Puccetti A, Beri R et al (2002) The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions. J Rheumatol 29:1914–1919PubMed
57.
Fassbender HG, Fassbender R (1992) Synovial characteristics of seronegative spondarthritides. Clin Investig 70:706PubMedCrossRef
58.
Espinoza LR, Vasey FB, Espinoza CG et al (1982) Vascular changes in psoriatic synovium. A light and electron microscopic study. Arthritis Rheum 25:677–684PubMedCrossRef
59.
Fearon U, Griosios K, Fraser A et al (2003) Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 30:260–268PubMed
60.
Ritchlin C, Haas-Smith SA, Hicks D et al (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25:1544–1552PubMed
61.
Austin LM, Ozawa M, Kikuchi T et al (1999) The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752–759PubMedCrossRef
62.
Szodoray P, Alex P, Chappell-Woodward CM et al (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46:417–425
63.
McGonagle D, Gibbon W, O’Connor P et al (1998) Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 41:694–700PubMedCrossRef
64.
Laloux L, Voisin MC, Allain J et al (2001) Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60:316–321PubMedCrossRef
65.
Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44:2112–2117PubMedCrossRef
66.
Ribbens C, Martin y Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef
67.
Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRef
68.
Ritchlin CT, Haas-Smith SA, Li P et al (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831PubMed
69.
Suda T, Takahashi N, Udagawa N et al (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357PubMedCrossRef
70.
Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef
71.
Udagawa N, Kotake S, Kamatani N et al (2002) The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4:281–289PubMedCrossRef
72.
Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505PubMedCrossRef
73.
Peng H, Wright V, Usas A et al (2002) Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751–759PubMed
74.
Stankler L (1969) An experimental investigation on the site of skin damage inducing the Koebner reaction in psoriasis. Br J Dermatol 81:534–535PubMedCrossRef
75.
Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971PubMedCrossRef
76.
Goupille P, Soutif D, Valat JP (1991) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 18:633PubMed
77.
Scarpa R, Del Puente A, Girolamo C di et al (1992) Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis 51:78–79PubMedCrossRef
78.
Langevitz P, Buskila D, Gladman DD (1990) Psoriatic arthritis precipitated by physical trauma. J Rheumatol 17:695–697PubMed
79.
Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMed
80.
Rasmussen JE (2000) The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J 19:153–154PubMedCrossRef
81.
Rahman MU, Ahmed S, Schumacher HR, Zeiger AR (1990) High levels of antipeptidoglycan antibodies in psoriatic and other seronegative arthritides. J Rheumatol 17:621–625PubMed
82.
Leung DY, Travers JB, Giorno R et al (1995) Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest 96:2106–2112PubMedCrossRef
83.
Travers JB, Hamid QA, Norris DA et al (1999) Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J Clin Invest 104:1181–1189PubMedCrossRef
84.
Muto M, Fujikura Y, Hamamoto Y et al (1996) Immune response to Streptococcus pyogenes and the susceptibility to psoriasis. Australas J Dermatol 37(Suppl 1):S54–S55PubMedCrossRef
85.
Valdimarsson H, Baker BS, Jonsdottir I et al (1995) Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16:145–149PubMedCrossRef
86.
Zampetti A, Gnarra M, Linder D et al (2010) Psoriatic pseudobalanitis circinata as a post-viral Koebner phenomenon. Case Rep Dermatol 2:183–188PubMedCrossRef
87.
Favre M, Orth G, Majewski S et al (1998) Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 110:311–317PubMedCrossRef
88.
Arnett FC, Reveille JD, Duvic M (1991) Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection. Rheum Dis Clin North Am 17:59–78PubMed
89.
Brancato L, Itescu S, Skovron ML et al (1989) Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter’s syndrome and related disorders associated with HIV infection. Rheumatol Int 9:137–141PubMed
90.
Rashmi R, Rao KS, Basavaraj KH (2009) A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 34:658–663PubMedCrossRef
91.
Tekin NS, Tekin IO, Barut F, Sipahi EY (2007) Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007:78454PubMed
92.
Yildirim M, Inaloz HS, Baysal V, Delibas N (2003) The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 17:34–36PubMedCrossRef
93.
Rocha-Pereira P, Santos-Silva A, Rebelo I et al (2004) The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150:917–928PubMedCrossRef
94.
Jongh GJ de, Zeeuwen PL, Kucharekova M et al (2005) High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 125:1163–1173PubMedCrossRef
95.
Bowes J, Barton A (2010) The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med 10:177–183PubMed
96.
Brockbank J, Gladman D (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457PubMedCrossRef
97.
Cantini F, Niccoli L, Nannini C et al (2010) Psoriatic arthritis: a systematic review. Int J Rheum Dis 13:300–317PubMedCrossRef
98.
Chandran V, Rahman P (2010) Update on the genetics of spondyloarthritis – ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol 24:579–588PubMedCrossRef
99.
Coates LC, Helliwell PS (2010) Disease measurement – enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 24:659–670PubMedCrossRef
100.
Mease PJ (2011) Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 70(Suppl 1):i77–i84PubMedCrossRef
101.
Rudwaleit M, Taylor WJ (2010) Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Pract Res Clin Rheumatol 24:589–604PubMedCrossRef
102.
Lories RJ, Vlam K de, Luyten FP (2010) Are current available therapies disease-modifying in spondyloarthritis? Best Pract Res Clin Rheumatol 24:625–635PubMedCrossRef
103.
Maejima H, Taniguchi T, Watarai A, Katsuoka K (2010) Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol 49:901–906PubMedCrossRef
104.
Antoni C, Krueger GG, Vlam K de et al (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157PubMedCrossRef
105.
McGonagle D, Lories RJ, Tan AL, Benjamin M (2007) The concept of a „synovio-entheseal complex“ and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 56:2482–2491PubMedCrossRef
106.
McGonagle D, Tan AL, Benjamin M (2009) The nail as a musculoskeletal appendage – implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 218:97–102PubMedCrossRef
107.
Jamnitski A, Visman IM, Peters MJ et al (2011) Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 70:875–876PubMedCrossRef
108.
Peters MJ, Eijk IC van, Smulders YM et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37:161–166PubMedCrossRef
109.
Angel K, Provan SA, Gulseth HL et al (2010) Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55:333–338PubMedCrossRef
110.
Eijk IC van, Peters MJ, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68:362–366PubMedCrossRef
111.
Tam LS, Li EK, Shang Q et al (2011) Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 70:705–706PubMedCrossRef
112.
Pischon N, Pischon T, Gulmez E et al (2010) Periodontal disease in patients with ankylosing spondylitis. Ann Rheum Dis 69:34–38PubMedCrossRef
113.
Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef
114.
Skoumal M, Haberhauer G, Fink A et al (2008) Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol 26:1087–1090PubMed
115.
Spoorenberg A, Heijde D van der, Klerk E de et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMed
116.
Ujfalussy I, Koo E (2003) Measurement of disease activity in psoriatic arthritis. Extended report. Z Rheumatol 62:60–65PubMedCrossRef
117.
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110PubMedCrossRef
118.
Coates LC, Cook R, Lee KA et al (2010) Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 62:970–976CrossRef
119.
Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17PubMedCrossRef
120.
Helliwell PS, Marchesoni A, Peters M et al (1991) Cytidine deaminase activity, C reactive protein, histidine, and erythrocyte sedimentation rate as measures of disease activity in psoriatic arthritis. Ann Rheum Dis 50:362–365PubMedCrossRef
121.
Laurent MR, Panayi GS, Shepherd P (1981) Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 40:66–69PubMedCrossRef
122.
Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385–390PubMedCrossRef
123.
Mease PJ, Kivitz AJ, Burch FX et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33:712–721PubMed
Metadaten
Titel
Psoriasisarthritis
Eine bleibende Herausforderung für Rheumatologen und Patienten – Teil 1: Epidemiologie, Pathogenese und Klinik
verfasst von
S. Finzel
M. Englbrecht
Publikationsdatum
01.10.2011
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 8/2011
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-011-0860-0

Weitere Artikel der Ausgabe 8/2011

Zeitschrift für Rheumatologie 8/2011 Zur Ausgabe

Mitteilungen der DGRh

Mitteilungen der DGRh

Leitthema

Universitärer Beitrag zur Implementierung des Treat-To-Target-Konzepts in der Rheumatologie

Hot Topics

Ist die Fibromyalgie eine Viruserkrankung?

Leitthema

„Treat-to-Target“ aus Sicht der Betroffenen

Leitthema

Das Curriculum „Rheumatologische Fachassistenz DGRh-BDRh“ als Weg der Professionalisierung medizinischer Assistenzberufe

Leitthema

„Treat-to-Target“ (T2T) aus der Sicht der stationären Rheumatologie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise